What do systematic reviews say?

SGLT2 inhibitors vs placebo

Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower all‐cause death median compared with placebo (high certainty).

• Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes 2024 · Cochrane Headline outcomes only
  RR 0.86 [0.81, 0.92]
  20 studies · 44397 participants
  High
• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 2933 participants
  Very low